Abstract
The prognosis of primary hyperoxaluria (PH) is not only related to endogenous oxalate production and the response (if any) to pyridoxine (in type I), but is greatly influenced by extrarenal factors like dehydration. The earlier the diagnosis of PH, the better the chances of improving the prognosis in individual patients. Measures to enhance the solubility of calcium oxalate are important. Besides ensuring at all times a generous fluid intake (>2 l/m2), administration of alkali citrate (0.15 g/kg), which has not been advocated so far in PH, appears very promising. We studied the effect of sodium citrate in six patients with PH. Mean urinary citrate excretion (mmol/day per 1.73 m2) without oral citrate was very low (0.57) and rose to 2.49 with citrate administration. This was accompanied by a significant decrease in the calcium oxalate saturation (calculated by equil 2) from 11.7 to 6.9 (P<0.05). Treatment in five patients over 10–36 months resulted in improved (1) or stabilized (4) renal function and reduced passage of stones. Additional measures include restriction of salt and of oxalate-rich food. We conclude that long-term administration of alkali citrate is beneficial in patients with PH.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Danpure CJ, Jennings PR, Watts RWE (1987) Enzymological diagnosis of primary hyperoxaluria type I by measurement of hepatic alanine: glyoxylate aminotransferase activity. Lancet I: 289–291
Seargeant LE, deGroot GW, Dilling LA, Mallory CJ, Haworth JC (1991) Primary oxaluria type 2 (l-glyceric aciduria), a rare cause of nephrolithiasis in children. J Pediatr 118: 912–914
Wharton R, D'Agati V, Magun AM, Whitlock R, Kunis CL, Appel GB (1990) Acute deterioration of renal function associated with enteric hyperoxaluria. Clin Nephrol 34: 116–121
Noel C, Sault M, Dhont J, Gosselin B, Leclet H, Marie A, Sebert JL, Lemaguer D, Lelièvre G (1989) Primary hyperoxaluria diagnosed after renal transplantation. J Nephrol 1: 43–45
Leumann EP, Dietl A, Matasovic A (1990) Urinary oxalate and glycolate excretion in healthy infants and children. Pediatr Nephrol 4: 493–497
Barratt TM, Kasidas GP, Murdoch I, Rose GA (1991) Urinary oxalate and glycolate excretion and plasma oxalate concentration. Arch Dis Child 66: 501–503
Schaumburg H, Kaplan J, Windebank A, Vick N, Rasmus S, Pleasure D, Brown MJ (1983) Sensory neuropathy from pyridoxine abuse. N Engl J Med 309: 445–448
DeZegher FE, Wolff ED, Heijden J van der, Sukhai RN (1984) Oxalosis in infancy. Clin Nephrol 22: 114–120
Yendt ER, Cohanim M (1985) Response to physiologic dose of pyridoxine in type I primary hyperoxaluria. N Eng J Med 312: 953–957
Reusz GS, Latta K, Hoyer PF, Byrd DJ, Ehrich JHH, Brodehl J (1990) Evidence suggesting hyperoxaluria as a cause of nephrocalcinosis in phosphate-treated hypophosphataemic rickets, Lancet 335: 1240–1243
Oestberg O (1931) Studien über die Zitronensäureausscheidung der Menschenniere in normalen und pathologischen Zuständen. Scand Arch Physiol 62: 81–212
Sutor DJ, Percival JU, Dooncen S (1979) Urinary inhibitors of the formation of calcium oxalate. Br J Urol 52: 253–255
Hamm LL (1990) Renal handling of citrate. Kidney Int 38: 728–735
Butz M, Dulce HJ (1981) Enhancement of urinary citrate in oxalate stoneformers by the intake of alkaline salts. In: Smith LH, Robertson WG, Finlayson B (eds) Urolithiasis. Plenum, New York, pp 881–884
Sakhaee K, Alpern R, Jacobson HR, Pak CYC (1991) Contrasting effects of various potassium salts on renal citrate excretion. J Clin Endocrinol Metab 72: 396–400
Pak CYC, Fuller C, Sakhaee K, Preminger GM, Britton F (1985) Long-term treatment of calcium nephrolithiasis with potassium citrate. J Urol 134: 11–19
Classen A, Hesse A (1987) Measurement of urinary oxalate. An enzymatic and an ion chromatographic method compared. J Clin Chem Clin Biochem 25: 95–99
Möllering H, Gruber W (1966) Determination of citrate with citrate lyase. Anal Biochem 17: 369–375
Werness PG, Brown CM, Smith LH, Finlayson B (1985) Equil 2, a basic computer program for the calculation of urinary saturation. J Urol 134: 1242–1244
Bach D, Hesse A, Bernal-Sprekelsen MS, Nemath S (1989) Normal values of lithogenic and inhibitory substances in the urine of healthy children. In: Walker V, Sutton R, Cameron E, Pak C, Robertson W (eds) Urolithiasis, Plenum, New York, pp 775–776
Leumann EP (1985) Primary hyperoxaluria, an important cause of renal failure in infancy. Int J Pediatr Nephrol 6: 13–16
Preminger GM, Sakhaee K, Skurla C, Pak CYC (1985) Prevention of recurrent calcium stone formation with potassium citrate therapy in patients with distal renal tubular acidosis. J Urol 134: 20–23
Fleisch H, Bisaz S, Care AD (1964) Effect of orthophosphate on urinary pyrophosphate excretion and the prevention of urolithiasis. Lancet 1: 1065–1067
Dent CE, Stamp TC (1970) Treatment of primary hyperoxaluria. Arch Dis Child 45: 735–745
Boddy SA, Duffy PG, Barratt TM, Whitfield HN (1988) Hyperoxaluria and renal calculi in children. The role of extracorporeal shock wave lithotripsy. Proc R Soc Med 81: 604–605
Watts RWE, Veall N, Purkiss P (1984) Oxalate dynamics and removal rates during haemodialysis and peritoneal dialysis in patients with primary hyperoxaluria and severe renal failure. Clin Sci 66: 591–597
Watts RWE, Danpure CJ, DePauw L, Toussaint C (1991) Combined liver-kidney and isolated liver transplantations for primary hyperoxaluria type 1. The European experience. Nephrol Dial Transplant 6: 502–511
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Leumann, E., Hoppe, B. & Neuhaus, T. Management of primary hyperoxaluria: efficacy of oral citrate administration. Pediatr Nephrol 7, 207–211 (1993). https://doi.org/10.1007/BF00864405
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00864405